Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. develops clinical-stage neuroplastogen-derived therapeutics focused on mental health and substance-use disorders. News for CMND centers on CMND-100, the company's proprietary non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder, including clinical-trial safety, tolerability, pharmacokinetic and preliminary efficacy updates from a multinational Phase I/IIa study.
Company updates also cover intellectual-property activity for psychedelic and neuroplastogen compounds, including patent applications and licensed development rights tied to PTSD and other mental health disorders. Additional recurring themes include FDA-related clinical communications, data-safety monitoring reviews, clinical-site progress and scientific presentations around MEAI.
SciSparc (Nasdaq: SPRC) reported that its subsidiary NeuroThera Labs (TSXV: NTLX) and collaborator Clearmind Medicine (Nasdaq: CMND) have advanced their partnership with U.S. publication of a patent application covering a novel combination of MDMA and N-acylethanolamines, such as palmitoylethanolamide (PEA), for treating PTSD, anxiety and eating disorders.
According to SciSparc, the application, published by the U.S. Patent and Trademark Office, expands a joint intellectual property portfolio that now includes 13 published patent applications globally. The filing describes embodiments where PEA may influence MDMA’s therapeutic potency, dosing, side effects and therapeutic window. The development coincides with the U.S. FDA’s July 14, 2026 final guidance on psychedelic drug development, which explicitly includes MDMA and outlines clinical trial, safety and regulatory considerations, providing additional regulatory context for the collaboration’s MDMA-PEA program.
Clearmind Medicine (Nasdaq: CMND) reported a key intellectual property milestone with U.S. publication of its patent application covering a novel combination of MDMA and N-acylethanolamines, including palmitoylethanolamide (PEA), for treating PTSD, anxiety and eating disorders. The application, published by the USPTO, stems from Clearmind’s collaboration with NeuroThera Labs, which integrates NeuroThera’s PEA technology into Clearmind’s psychedelic-derived programs and contributes to a joint portfolio of 13 patent applications worldwide. The filing outlines embodiments in which PEA may enhance MDMA’s therapeutic potency, reduce dose requirements, mitigate side effects and broaden MDMA’s therapeutic window. This progress coincides with the FDA’s July 13, 2026 final guidance on psychedelic drug development, which explicitly includes MDMA and details regulatory expectations for clinical investigations.
Clearmind Medicine (Nasdaq: CMND) reported that an independent Data and Safety Monitoring Board unanimously approved advancing its FDA‑regulated Phase I/II trial of CMND‑100 for Alcohol Use Disorder (AUD) to Parts B and C, after Part A met its primary safety endpoint in healthy participants across all planned doses.
Part B will test 80 mg and 160 mg doses in two cohorts of six patients with moderate to severe AUD, assessing safety, tolerability and early clinical activity. Part C, a double‑blind, placebo‑controlled segment in healthy participants, will further characterize safety at 160 mg over five days. The multi‑center study also evaluates pharmacokinetics and preliminary efficacy in reducing drinking and craving.
Clearmind Medicine (Nasdaq: CMND) reported positive permeation results from its intranasal MEAI (5‑Methoxy‑2‑aminoindane) development program. Using Franz diffusion cells under physiologically relevant conditions, both the proprietary intranasal MEAI formulation and a conventional MEAI solution achieved rapid, extensive membrane permeation.
By 180 minutes, cumulative permeation reached 97.35% for intranasal MEAI and 98.34% for the conventional formulation, indicating that enhanced nasal residence time from Clearmind’s mucoadhesive intranasal platform does not materially impair MEAI transport. Combined with earlier ex vivo mucoadhesion data showing substantially longer nasal retention, the company highlights three achievements: stable, fully soluble formulation, enhanced mucoadhesion with prolonged nasal residence, and preserved permeation kinetics supporting continued intranasal MEAI development.
Clearmind Medicine (Nasdaq: CMND) reported that an independent Data and Safety Monitoring Board (DSMB) unanimously approved advancing its FDA‑regulated Phase I/II clinical trial of CMND‑100 for Alcohol Use Disorder (AUD) from Part A to Parts B and C.
According to Clearmind Medicine, Part A in healthy participants met its primary safety endpoint, showing a favorable safety and tolerability profile across all planned dose levels. Part B will, for the first time, test CMND‑100 in human patients with moderate to severe AUD, enrolling two sequential cohorts of six patients at 80 mg and 160 mg doses to assess safety, tolerability and early activity signals such as reduced alcohol consumption and craving. Part C will run concurrently in healthy volunteers, using a 160 mg fixed daily dose for five days in a double‑blind, placebo‑controlled design to further characterize safety and tolerability. The multicenter trial is conducted at leading sites including Johns Hopkins University, Yale School of Medicine, Tel Aviv Sourasky Medical Center and Hadassah Medical Center.
Clearmind Medicine (Nasdaq: CMND) signed a non-binding Letter of Intent to acquire a 51% majority stake in a company that develops intelligent wireless EV charging solutions for automated parking systems and autonomous mobile platforms. The target’s technology supports continuous wireless charging up to 10 kW, requires no cables or manual connections, and integrates with robotic parking systems for real-time energy management.
According to Clearmind, the aggregate purchase price for the majority stake is $2.5 million. As a condition to closing, Clearmind will also provide a $1.5 million loan to the acquired company, bearing 4% annual interest and maturing two years after closing. Completion of the acquisition remains subject to definitive agreements, final due diligence, and other closing conditions.
Clearmind Medicine (Nasdaq: CMND) reported positive safety and tolerability findings from Part A of its FDA‑regulated Phase I/II trial of CMND‑100, an oral MEAI‑based, non‑hallucinogenic neuroplastogen being developed for Alcohol Use Disorder (AUD). All 24 healthy volunteers across four single‑ascending‑dose cohorts (approximately 20, 40, 80 and 160 mg) completed treatment per protocol.
The trial met its primary endpoint of safety and tolerability, with a consistent safety profile across all dose levels, including the highest dose, and no serious adverse events observed. According to Clearmind, these results support continued clinical advancement of CMND‑100 and reduce key early‑stage development risks as the program moves toward dosing AUD patients. The multicenter study is conducted under FDA oversight at leading sites in the United States and Israel, including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center and Hadassah Medical Center.
Clearmind Medicine (Nasdaq: CMND) reported the successful completion of treatment for all participants in Part A of its ongoing FDA-regulated Phase I/II clinical trial of CMND-100 for Alcohol Use Disorder (AUD). All 24 participants across cohorts 1 through 4 completed treatment in line with the study protocol.
The company is now assessing the Part A dataset and, if results remain favorable, plans to initiate the next stage of the clinical program in AUD patients. According to Clearmind, this multicenter trial is conducted under FDA oversight at leading research sites in the United States and Israel, including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. Management highlighted the alignment with protocol and collaboration with world-class centers as they work to advance CMND-100 as a therapeutic candidate for AUD.
Clearmind Medicine (Nasdaq: CMND) has filed a patent application with the Hong Kong Patent Office for innovative psychedelic compounds targeting treatment of PTSD and other mental health disorders. The filing is part of Clearmind’s exclusive worldwide licensing agreement with Yissum, under which Clearmind holds global rights to develop, manufacture, and commercialize novel compounds developed at Hebrew University.
According to Clearmind, this expands its global IP coverage, which currently includes nineteen patent families and 32 granted patents, and supports access to the Asian market. The company cites reports valuing the global PTSD treatment market at about USD 18.5 billion in 2025, projected to reach USD 30.2 billion by 2035.
Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotechnology company developing non-hallucinogenic neuroplastogen-derived treatments for Alcohol Use Disorder (AUD), addiction and weight management, highlighted recent U.S. federal actions supporting psychedelic-based therapies. The company noted final FDA guidance on psychedelic clinical investigations, a planned public hearing on therapeutic psychedelic use, and new Memoranda of Understanding and collaborative initiatives among HHS, VA, FDA, NIDA, ARPA-H and HRSA.
According to Clearmind Medicine, CEO Dr. Adi Zuloff-Shani welcomed these steps as expanding treatment approaches for serious neuropsychiatric and addiction disorders. The company’s lead candidate, CMND-100 (MEAI / 5-MeO-AI), is a non-hallucinogenic compound in FDA-cleared Phase I/IIa clinical trials for AUD at institutions including Yale University and Johns Hopkins.